Valentina Boni, MD, PhD

Valentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.

Valentina Boni, MD, PhD, spoke about the safety profile observed of lurbinectedin monotherapy and future analyses for patients with BRCA1/2-associated metastatic breast cancer.

Valentina Boni, MD, PhD, spoke about the rationale behind using lurbinectedin monotherapy for pretreated BRCA1/2-associated metastatic breast cancer.